HK Stock Market Move | LEE'S PHARM (00950) afternoon rose more than 27%, the new indication application for Saccozumab Monoclonal Antibody was approved. Institutions say they are focusing on palliative care.

LEE'S PHARM (00950) surged over 27% in the afternoon, rising 20.9% as of the time of writing, to 2.43 Hong Kong dollars, with a trading volume of 44.9021 million Hong Kong dollars. On the news front, LEE'S PHARM previously released its interim results, with the group earning 695 million Hong Kong dollars, a 5.5% increase year-on-year; mainly driven by the strong sales performance of the group's product portfolio. The company's net profit attributable to shareholders for the first half of 2025 was 67.185 million Hong Kong dollars, a 7.5% increase year-on-year. It is worth noting that at the end of July, LEE'S PHARM announced that its subsidiary Zhaoke Oncology's new indication for the anti-PD-L1 monoclonal antibody Saccizumab was approved for marketing. In addition, Zhongtai released a research report stating that in recent years, innovative treatments such as dual antibodies, ADCs, small molecule targeted drugs (TKIs), and cell therapies have extended the overall survival of cancer patients, with the quality of life (QoL) of cancer patients being an important issue of concern in clinical practice. The palliative care discipline focuses on issues related to cancer cachexia and breakthrough cancer pain. The investment bank points out that LEE'S PHARM's development of the fentanyl aerosol inhaler AZ003 can effectively control breakthrough cancer pain, with its Phase 2 clinical results to be presented at ASCO in 2024. The bank believes that this track will see the emergence of several major drugs in the future, which investors should pay attention to.